These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9180431)

  • 21. Clinical practice guidelines for maintaining adequate iron status with intravenous iron dextran in hemodialysis patients.
    Peacock E; Lindenfeld SM
    ANNA J; 1999 Jun; 26(3):337-43. PubMed ID: 10633605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iron management during recombinant human erythropoietin therapy.
    Van Wyck DB
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):9-13. PubMed ID: 2757026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patients.
    Besarab A; Dalton CL
    Nephrol Nurs J; 2001 Aug; 28(4):429-34. PubMed ID: 12143465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of renal anemia with iron in hemodialysis patients in General Hospital Bjelovar].
    Lovcić V; Vujić J; Basić-Jukić N; Janković RI; Kurtović I; Dzapo M; Lovcić P
    Acta Med Croatica; 2011 Oct; 65 Suppl 3():45-8. PubMed ID: 23120815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Categorizing the response to Epoetin alfa therapy. Case study of the anemic patient.
    Watson C
    ANNA J; 1999 Dec; 26(6):629-32. PubMed ID: 10876477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of iron in patients on chronic dialysis: mistake and misconceptions.
    Sakiewicz P; Paganini E
    J Nephrol; 1998; 11(1):5-15. PubMed ID: 9561479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transferrin receptor assay and zinc protoporphyrin as markers of iron-deficient erythropoiesis in end-stage renal disease patients.
    Baldus M; Walter H; Thies K; Anders C; Stein M; Hellstern P; Brass H
    Clin Nephrol; 1998 Mar; 49(3):186-92. PubMed ID: 9543601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of rHuEPO resistance in CRF patients: a clinical protocol at Winthrop-University Hospital.
    Trenkle JA
    ANNA J; 1998 Jun; 25(3):333-8, 344. PubMed ID: 9801489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nononcologic use of human recombinant erythropoietin therapy in hospitalized patients.
    Fischer MA; Morris CA; Winkelmayer WC; Avorn J
    Arch Intern Med; 2007 Apr; 167(8):840-6. PubMed ID: 17452549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to design an anemia management protocol.
    Senger JM; Trenkle JA; St John WD
    ANNA J; 1998 Apr; 25(2):235-40. PubMed ID: 9801503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of nephrology nurses and technicians in the implementation of NKF-DOQI.
    Bender K; Swartz MD
    Nephrol News Issues; 1999 Apr; 13(4):21-3. PubMed ID: 10418445
    [No Abstract]   [Full Text] [Related]  

  • 32. Case management of the anemic patient. Epoetin alfa: focus on oral iron supplementation.
    Sasak C
    ANNA J; 1991 Oct; 18(5):508-9. PubMed ID: 1953090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does iron cause bacterial infections in patients with end stage renal disease?
    Cieri E
    ANNA J; 1999 Dec; 26(6):591-6. PubMed ID: 10876474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous iron products.
    Johnson CA; Mason NA; Bailie GR
    Nephrol Nurs J; 2000 Feb; 27(1):66. PubMed ID: 10852694
    [No Abstract]   [Full Text] [Related]  

  • 35. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
    Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
    J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron overload in the erythropoietin era.
    Robbins KC
    Nephrol Nurs J; 2000 Apr; 27(2):227-31. PubMed ID: 11111550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Back to the basics in iron management for the patient receiving epoetin therapy.
    Kirlin L
    ANNA J; 1991 Aug; 18(4):428. PubMed ID: 1872645
    [No Abstract]   [Full Text] [Related]  

  • 38. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tools for analyzing trends in anemia management case study of the anemic patient.
    Aiello J
    Nephrol Nurs J; 2000 Feb; 27(1):57-60. PubMed ID: 10852692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring the content of reticulocyte hemoglobin (CHr) as the progression of anemia in nondialysis chronic renal failure (CRF) patients.
    Tsuchiya K; Saito M; Okano-Sugiyama H; Nihei H; Ando M; Teramura M; Iwamoto YS; Shimada K; Akiba T
    Ren Fail; 2005; 27(1):59-65. PubMed ID: 15717636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.